A Multicenter Phase II Study of Personalized FOLFIRI-Cetuximab for Safe Dose Intensification

We conducted a multicenter proof of concept phase II trial in patients with advanced colorectal cancer receiving FOLFIRI-Cetuximab regimens to explore individual drug tailoring using pharmacogenetics and PK-monitoring.

Source: Seminars in Oncology - February 9, 2017 Category: Cancer & Oncology Authors: O. Capitain, J.P. Metges, M. Boisdron-Celle, A. Adenis, J.L. Raoul, T. Lecomte, Y.H. Lam, R. Faroux, C. Masliah, A.L. Poirier, V. Berger, A. Morel, E. Gamelin Source Type: research